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salons. M. conceptionense belongs to 
the M. fortuitum group and was iso-
lated in a posttraumatic osteitis inﬂ  am-
mation (10). M. chimaera belongs to 
MAC and has been isolated only in pa-
tients with pulmonary disorders but not 
from immunocompromised patients. 
The authors reported that the isolate 
showed unusually high virulence. We 
isolated this species for the ﬁ  rst time 
in an environmental sample. It could 
belong to the transitory ﬂ  ora of the H 
cooling tower because it was isolated 
only once in our samples. Cooling 
towers already had been investigated 
for slow-growing mycobacteria (1), 
and our study showed they also can 
be an environmental source of rapidly 
growing NTM pathogens. In our pro-
cedure for amebal co-cultures, incu-
bation cannot last >10 days because 
amebae do not survive longer in Page’s 
amebal saline buffer. Moreover, agar 
plates were incubated for 10 days only, 
which explains why we could recover 
only rapidly growing mycobacteria. 
The cooling towers, already known as 
a source of dissemination of Legionel-
la spp., may disseminate mycobacteria 
in aerosols and be a previously nonrec-
ognized source of infection.
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To the Editor: The threat to pub-
lic health posed by Clostridium dif-
ﬁ  cile-associated disease (CDAD) con-
tinues to increase within and outside 
the United States. In a recent analysis, 
we detected a 23% annual increase in 
CDAD-related hospitalizations from 
2000 through 2005 and a near-dou-
bling in the associated age-adjusted 
case-fatality rate from 2000 through 
2004 (1). In view of the aging US pop-
ulation, this rapid growth, along with 
the increased virulence and diminished 
susceptibility to antimicrobial drug 
treatments, if sustained, will not only 
strain the US healthcare system (2,3) 
but also will cause signiﬁ  cant illness 
and death. For this reason, understand-
ing up-to-date trends in CDAD-related 
hospitalizations is critical. Since the 
Agency for Healthcare Research and 
Quality recently made available its 
2006 update to the National Inpatient 
Sample (NIS) data (4) on the Health-
care Costs and Utilization Project Net 
(HCUPNet) website (5), I explored 
the trends in CDAD hospitalizations 
beyond our 2005 estimates.
From the HCUPNet website (5), 
I identiﬁ  ed CDAD-related hospitaliza-
tions for 2000–2006 in the NIS data 
(4). The NIS is a stratiﬁ  ed 20% sam-
ple of US community hospitals, and 
data are weighted to provide national 
estimates (4). CDAD was identiﬁ  ed 
by presence of the International Clas-
siﬁ   cation of Diseases, 9th revision, 
Clinical Modiﬁ  cation  (ICD-9-CM) 
diagnosis code 8.45 (intestinal infec-
tion with Clostridium difﬁ  cile), and 
the numbers of discharges per year 
were age-stratiﬁ  ed.  To  benchmark 
CDAD incidence against the general 
growth in hospitalizations over time, 
I obtained age-stratiﬁ   ed numbers of 
total hospitalizations from HCUPNet 
122  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 1, January 2009LETTERS
for each year and derived CDAD-
related hospitalization incidence as a 
function of total annual US hospital-
ization volume. I also obtained censal 
and intercensal data on the numbers 
and demographic characteristics of 
the US population during 2000–2006 
from the US Census Bureau (6). On 
the basis of these data, I calculated 
age-speciﬁ  c hospitalization incidence 
rates and repeated these analyses by 
census region (Northeast, Midwest, 
South, and West). Finally, I explored 
trends in CDAD principal diagnosis 
hospitalizations as a proportion of all 
CDAD-related hospitalizations.
Overall, the rate of growth 
in CDAD-related hospitalizations 
slowed in 2006, with a crude volume 
increase of 6.7% over 2005; the dif-
ference in the raw volume from 2005 
through 2006 did not reach statistical 
signiﬁ  cance (p = 0.33). When hospi-
talization incidence was stratiﬁ  ed by 
age, the greatest increase from 2005 
through 2006 occurred in the 45- to 
64-year age group (7.2%, from 8.48 to 
9.09 cases per 10,000 population) and 
the smallest increase occurred in the 
>85-year group (0.9%, from 110.71 to 
111.70 per 10,000 population); the 18- 
to 44-year (5.7%, from 2.26 to 3.39 per 
10,000 population) and 65- to 84-year 
groups (5.1%, from 46.57 to 48.96 
per 10,000 population) had results be-
tween the other 2 groups (Table). Al-
though consistently higher in women 
than men, the population incidence of 
CDAD-related hospitalizations in men 
(4.0%) and women (5.0%) rose simi-
larly (Table). In addition, although the 
volume of CDAD principal diagnosis 
had not previously exceeded 25% of 
total CDAD-related hospitalizations 
(1), in 2006 this proportion increased 
to 28% (Table). In examining CDAD 
hospitalization trends regionally, in 
the Northeast I found a directional re-
duction in incidence at both the total 
hospitalizations level and population 
level. CDAD-related hospitalizations 
in the Midwest, South, and West con-
tinued to increase (Table).
While previously growing at the 
unsustainable rate of 23% per year, 
from 2005 through 2006, CDAD-
related hospitalizations in adults in-
creased 6.7%, representing a potential 
considerable slowing of the epidemic. 
Whereas the number and incidence 
of CDAD-related hospitalizations de-
creased in the Northeast, such hospi-
talizations in the remaining regions 
had sustained, albeit smaller than in 
prior years, increases. Additionally, 
the proportion of all CDAD-related 
hospitalizations for which CDAD was 
the principal diagnosis for the hospi-
talization rose to 28% overall. Given 
the deﬁ  nition of a “principal diagno-
sis” in the NIS database as “that con-
dition established after study to be 
chieﬂ  y responsible for occasioning the 
admission of the patient to the hospi-
tal for care; the principal diagnosis is 
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Table. Incidence of Clostridium difficile–related hospitalizations among US adults, 2000–2006, by age group and region* 
Year 
Hospitalization variable  2000 2001 2002 2003 2004 2005 2006
All US adults per 10,000 population 
 18–44  y  1.31 1.33 1.66 1.71 1.96 2.26 2.39
 45–64  y  4.53 4.58 5.92 6.31 7.20 8.48 9.09
 65–84  y  22.41 23.94 31.61 33.74 39.06 46.57 48.96
>85 y  52.09 57.03 70.15 74.99 89.39 110.71 111.70
Principal diagnosis CDAD as a proportion of total CDAD, % 
 18–44  y  26.3 26.8 26.9 26.1 28.1 29.1 30.7
 45–64  y  24.4 25.2 24.4 23.2 24.3 25.5 27.4
 65–84  y  22.8 23.7 23.3 22.8 23.8 24.9 27.8
>85 y  22.1 24.4 23.6 23.2 24.0 25.0 29.8
By sex per 10,000 population 
 M  4.10 6.30 5.71 6.03 7.03 8.59 9.00
 F  5.72 6.83 7.71 8.32 9.71 11.72 12.29
By sex per 1,000 hospitalizations 
 M  3.83 5.81 5.24 5.54 6.43 7.79 8.13
 F  3.81 4.51 5.04 5.45 6.36 7.66 8.02
Regionally per 10,000 population 
 Northeast  7.05 7.59 9.30 10.40 10.73 14.46 14.28
 Midwest  5.70 5.32 7.96 8.51 9.86 11.32 12.27
 South  4.05 4.98 6.26 6.49 8.19 9.50 9.64
 West  3.72 3.52 4.10 4.39 5.39 6.73 7.32
Regionally per 1,000 hospitalizations 
 Northeast  5.15 5.52 6.74 7.47 7.64 10.17 10.00
 Midwest  4.36 3.98 5.90 6.31 7.26 8.26 8.97
 South  2.97 3.59 4.49 4.66 5.89 6.83 7.06
 West  3.41 3.24 3.76 4.00 4.92 6.16 6.85
*CDAD, C. difficile–associated disease. LETTERS
always the reason for admission,” this 
rise could represent altered disease 
manifestation, severity, or virulence.
In summary, the previously noted 
rate of growth in CDAD-related hospi-
talizations in US adults appears to have 
slowed somewhat in 2006. The encour-
aging downward trend in CDAD in the 
Northeast requires further exploration. 
Of concern is the increasing propor-
tion of CDAD-related hospitalizations 
coded as the primary reason for admis-
sion because this may signal a change 
in characteristics of the disease. Given 
that the new data represent only 1 year, 
and the difference between the raw 
numbers from 2005 through 2006 did 
not reach statistical signiﬁ  cance, these 
ﬁ   ndings need to be interpreted with 
caution and monitored annually. In gen-
eral, although helpful, most nationwide 
data have a considerable lag time. In 
this and other resistant diseases sweep-
ing the US hospitals, real-time surveil-
lance data are needed for more prompt 
and actionable policy development.
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To the Editor: In 2005, preva-
lence of human tuberculosis (TB) 
in Uganda was 559 cases/100,000 
population (1). In 2002, the average 
number of extrapulmonary TB cases 
in humans, considered a crude indi-
cator of the level of bovine TB, was 
7.5% of TB cases for Uganda and 6% 
for Mbarara district, the main Ugan-
dan milk basin (2). Worldwide, the 
proportion of human cases caused by 
Mycobacterium bovis has accounted 
for 3.1% of all forms of TB (3). Al-
though zoonotic TB is more often re-
ported as an extrapulmonary disease, 
recent publications report that 0.4%–
10% of sputum isolates from patients 
in African countries are M. bovis (3). 
These studies, however, give little 
information about the cattle environ-
ment. A 2002 survey of dairy cattle in 
Mbarara district reported that 74% of 
herds and 6% of individual animals 
were reactive to the single tuberculin 
test (4). However, this test does not 
differentiate between Mycobacterium 
species involved. We therefore ex-
plored whether M. bovis might be a 
major threat to human health in this 
region.
From September 2004 through 
January 2005, we surveyed 658 pa-
tients who had been admitted to the 
Mbarara University Teaching Hospital 
TB ward after positive bacterial ﬁ  nd-
ings for at least 3 sputum smears or 
positive chest radiographs for smear-
negative patients. Of 90 randomly se-
lected patients, only 70 samples were 
available for analysis to differentiate 
the species in the M. tuberculosis com-
plex; the other samples were excluded 
because of contamination, lack of my-
cobacteria growth on culture, or postal 
delay in transportation of sample. The 
questionnaire asked about patients’ 
demographic data (including occupa-
tion), association with cattle, and milk 
consumption habits. Genomic DNA 
was extracted from the pellet culture 
of Middlebrook 7H9 broth (Difco; 
Cergy, France) as described previ-
ously (5). DNA samples were used to 
carry out PCRs and hybridization pro-
cesses; we used the GenoType MTBC 
kit (Hain Lifescience GmbH; Nehren, 
Germany) for differentiation in the M. 
tuberculosis complex, especially be-
tween  M. tuberculosis and M. bovis 
species (6).
Questionnaire responses showed 
that 27/64 (42.2%; 6 did not answer) 
patients had a history of raw milk con-
sumption; nevertheless, 20/24 (83%; 
3 did not answer) reported that they 
boiled fresh milk before consuming it, 
as did 54/60 (90% of all patients; 10 
did not answer). Eating undercooked 
or raw meat was reported by 91% of 
the patients. Most patients were adult 
males (ratio 2.14:0.97 male:female for 
the district population); 8.6% were <18 
years old (56% in the district); and av-
erage number of persons in household 
was 5.7 vs. 4.8 for the district (7). Of 
the samples, 8.6% were from extrapul-
monary sites.
After ampliﬁ  cation and hybrid-
ization of sample DNA, 69 samples 
were found to be M. tuberculosis, and 
1 was not a Mycobacterium species. 
Our sampling method would detect at 
least 1 case of M. bovis in n patient 
specimens if the prevalence of bovine 
TB was > p(0.033%) according to the 
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